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ABSTRACT
Histiocytic sarcoma is an uncommon malignancy in both humans and veterinary 
species. Research exploring the pathogenesis of this disease is scarce; thus, 
diagnostic and therapeutic options for patients are limited. Recent publications have 
suggested a role for the NLR, NLRX1, in acting as a tumor suppressor. Based on these 
prior findings, we hypothesized that NLRX1 would function to inhibit tumorigenesis 
and thus the development of histiocytic sarcoma. To test this, we utilized Nlrx1-
/- mice and a model of urethane-induced tumorigenesis. Nlrx1-/- mice exposed to 
urethane developed splenic histiocytic sarcoma that was associated with significant 
up-regulation of the NF-kB signaling pathway. Additionally, development of these 
tumors was also significantly associated with the increased regulation of genes 
associated with AKT signaling, cell death and autophagy. Together, these data show 
that NLRX1 suppresses tumorigenesis and reveals new genetic pathways involved in 
the pathobiology of histiocytic sarcoma.
INTRODUCTION
Histiocytic sarcoma is a rare, malignant neoplasm 
with a phenotypic profile consistent with an interstitial 
dendritic cell or macrophage origin. In human patients, this 
disease occurs most commonly in the intestinal tract, skin, 
soft tissue, and lymph nodes though case reports have also 
identified it in the central nervous system and stomach [1, 
2]. Definitive diagnosis is often difficult due to its variable 
clinical presentation, as well as, its similarities to other 
histiocytic disorders such as hemophagocytic syndrome, 
malignant histiocytosis and monocytic leukemia. While 
still rare, this neoplasm is more common in veterinary 
medicine, where it is primarily a disease of dogs. Indeed, 
the bulk of studies of histiocytic sarcoma have arisen from 
cases in veterinary medicine. Treatment options in both 
human and veterinary medicine are limited and include 
complete surgical resection (when possible) coupled with 
chemotherapy or palliative radiation. However, in all 
species, treatment is often unsuccessful and the disease is 
typically fatal.
Pattern recognition receptors (PRRs) are important 
components of the innate immune system that are involved 
in the promotion and/or regulation of inflammation. 
These receptors recognize pathogen associated molecular 
patterns (PAMPs) and/or damage associated molecular 
patterns (DAMPs), which are products released by stressed 
or dying cells. PRRs that have been shown to significantly 
modulate the pathogenesis of neoplasia, include the Toll-
like receptors (TLRs) and the NOD-like receptors (NLRs). 
TLRs are located on the surface of the cell, as well as, 
within endosomes and have been shown to play a role in 
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lung cancer, breast cancer, and colon cancer [3-7]. NLRs 
are intracellular sensors and are well-studied in the context 
of colitis associated colorectal cancer [8, 9]. However, 
their involvement in other neoplasms is generally less 
defined and currently an area of intense research focus.
At least 34 NLR family members have been 
identified in mice and at least 22 in humans, the majority 
of which have yet to be functionally characterized [10]. Of 
the characterized NLRs, the majority appear to function as 
molecular effectors that form multi-protein complexes. For 
example, the most widely studied NLR family members 
form a multi-protein complex with the adaptor protein 
ASC and caspase-1, termed the inflammasome that is 
responsible for the production of the mature forms of the 
pro-inflammatory cytokines IL-1β and IL-18. However, a 
second sub-group of NLRs has recently been characterized 
that primarily function as non-inflammasome forming, 
regulatory NLRs. Members of this sub-group include 
NOD1 and NOD2, NLRX1 and NLRC3 (reviewed in [9]).
NLRX1 has been shown to be an important regulator 
of critical pathways associated with both inflammation 
and tumorigenesis. These include roles in the inhibition 
of NF-κB signaling, Type-I IFN production, and ROS 
production, as well as, the promotion of autophagy [11-
15]. However, beyond these initial characterization 
studies, many questions remain unanswered regarding 
the function of this unique protein. The majority of 
studies investigating NLRX1 have focused on its role 
in host-pathogen interactions. However, the pathways 
modulated by NLRX1 are also typically dysregulated 
during tumorigenesis. Thus, we hypothesized that NLRX1 
significantly inhibits tumorigenesis through regulating 
one or more of these previously characterized pathways. 
Here, we utilized Nlrx1-/- mice in a model of urethane 
induced tumorigenesis. Our data reveal that Nlrx1-/- mice 
are sensitive to urethane treatment and develop histiocytic 
sarcoma in the spleen that is associated with increased NF-
κB signaling. We also identify a diverse range of genes 
associated with common cancer pathways, AKT signaling, 
cell death, and autophagy that are also significantly up-
regulated in the Nlrx1-/- mice during histiocytic sarcoma. 
Collectively, our results further confirm that NLRX1 
functions as a tumor suppressor and extends these findings 
to histiocytic sarcoma, which is an understudied cancer 
with few biomarkers.
RESULTS
NLRX1 is differentially regulated in multiple 
human cancers
To gain broader insight into the contribution of 
NLRX1 in cancer, we conducted a retrospective evaluation 
of publically available gene expression metadata compiled 
from 18 human studies (Figure 1A). Each study focused 
on a specific type or sub-type of cancer and evaluated 
gene expression levels between the tumor specimen 
and either adjacent healthy tissue or specimens from 
comparable tissue in unaffected subjects. The change in 
NLRX1 expression was deemed significant based on the 
parameters of each individual study. Our data analysis 
revealed that NLRX1 is differentially regulated in a diverse 
range of human cancers (Figure 1A). For example, at the 
extremes, NLRX1 was found to be up-regulated 2.72 
fold in squamous cell carcinoma of the skin compared 
to normal skin, while being down-regulated 8.1 fold in 
high grade myxoid liposarcoma tumors compared to 
normal adipose tissue (Figure 1A). While no human 
histiocytic sarcoma studies have been conducted, NLRX1 
gene expression data was evaluated for malignant fibrous 
histiocytoma (Figure 1A). Malignant fibrous histiocytoma, 
like histiocytic sarcoma, is controversial in origin though 
histiocytic cells are thought to be a major contributor. In 
both humans and canines, this is a soft tissue sarcoma and, 
in dogs, occurs most commonly in the spleen and skin. 
The fact that NLRX1 is downregulated in this neoplasm 
may suggest a similar pattern in human histiocytic 
sarcoma. Together, these data reveal that NLRX1 plays 
a complex role in tumorigenesis in humans and suggests 
that additional studies are needed to better define the 
contribution of this gene in patient populations.
NLRX1 deficiency results in increased cell 
proliferation and chemokine production
The role of NLRX1 in the regulation of pathways 
associated with tumorigenesis is not well defined. A recent 
pair of studies have suggested that NLRX1 functions as 
a tumor suppressor through modulating apoptosis [16, 
17]. In one study, NLRX1 expression was found to 
differentially regulate resistance to extrinsic and intrinsic 
apoptotic signals in transformed, but not primary murine 
embryonic fibroblasts [17]. In the other study, NLRX1 
was found to function as a tumor suppressor by regulating 
TNF induced apoptosis in immortalized cell lines [16]. 
In the same study, NLRX1 overexpression was found to 
compromise clonogenicity, growth and migration [16]. 
To complement these prior studies, we sought to directly 
evaluate the contribution of NLRX1 on cell proliferation 
and growth. Bone marrow derived macrophages were 
harvested from wild type and Nlrx1-/- mice and allowed 
to differentiate for 5-7 days following standard protocols 
[18]. Cells were quantified and re-plated at 275,000 cells/
ml in standard growth media without the addition of FBS 
(Figure 1B). Over the course of 24 hours, cells were 
counted using both trypan blue and a hemacytometer, as 
well as, propidium iodide (PI) staining and assessments 
with an automated cell counter (Figure 1B). Both live cells 
and dead cells were counted using these techniques. Under 
these conditions, wild type macrophages did not increase 
in number over the 24 hour time course. However, we did 
observe significant expansion of Nlrx1-/- macrophages 
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Figure 1: NLRX1 Gene Expression is Significantly Dysregulated in Diverse Human Neoplasms. A. A retrospective analysis 
of gene expression metadata from samples collected from human subjects revealed that NLRX1 expression was significantly dysregulated in 
a diverse range of cancer subtypes. Data shown were determined to be significant changes in NLRX1 expression between the tumor sample 
and either adjacent tissue from the same subject or a comparable tissue from an unaffected control subject based on the specific parameters 
established in each individual study. B-C. Macrophages from Nlrx1-/- mice rapidly proliferate and release increased cytokines associated 
with cell growth and migration. B) Bone marrow derived macrophages from Nlrx1-/- mice significantly expand under standard tissue culture 
conditions. C) Significant increases in Ccl2 (Monocyte Chemotactic Protein-1) and Csf3 (GCSF) gene expression were observed in Nlrx1-
/- macrophages compared to wild type macrophages. Data are representative of 5 independent studies. *p<0.05.
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over the 24 hour time course (Figure 1B). The Nlrx1-/-
 macrophages more than doubled the number of wild type 
macrophages 16 hours after re-plating (Figure 1B). Further 
assessments of gene expression revealed that chemokines 
associated with macrophage proliferation and recruitment, 
including Ccl2 (MCP1) and Csf3 (GCSF), were up-
regulated in Nlrx1-/- macrophages compared to the wild 
type cells (Figure 1C). Unlike the prior studies, we did 
not observe differences in cell death. However, it should 
be noted that the prior studies induced apoptosis through 
TNF stimulation, glycolysis inhibition, increased cytosolic 
calcium flux, and endoplasmic reticulum stress [16, 17]. 
The current study evaluated cells with minimal stimulation 
beyond the overnight incubation in serum-free conditions. 
Thus, it is highly likely that the differences in cell death 
are associated with cell type, temporal, and stimulation 
specific mechanisms.
NLRX1 attenuates disease pathogenesis 
following urethane exposure
To better characterize the role of NLRX1 in cancer, 
we subjected Nlrx1-/- mice to a urethane (ethyl carbamate)-
induced tumor model (Figure 2A). Urethane induced 
tumor formation is a prototypical and highly reproducible 
animal model of carcinogenesis that is traditionally 
utilized to study lung cancer [19-21]. Repeated urethane 
exposure consistently results in pulmonary adenoma and 
adenocarcinoma formation [21]. Similar to some human 
adenocarcinomas, urethane induces specific mutations in 
Kras at codon 61 and mutations in p53 during later stages 
of disease progression [20]. Wild type and Nlrx1-/- mice 
were administered weekly intraperitoneal injections of 1g/
kg body weight of urethane diluted in saline for a total of 
7 weeks (Figure 2A). Survival, weight loss, and clinical 
parameters associated with disease progression were 
routinely monitored. We evaluated disease progression 
and tumorigenesis at weeks 7 and 14. We did not observe 
any significant pathological changes at week 7, following 
the final urethane injection (Supplementary Figure 1). 
However, by week 14, 50% of the Nlrx1-/- mice had 
developed palpable masses in their peritoneal cavity 
and required euthanasia (Figure 2B). Additionally, the 
urethane treated Nlrx1-/- mice failed to thrive throughout 
the duration of the study and demonstrated significantly 
decreased weight gain compared with the wild type 
animals starting 5 weeks after the initial exposure to 
urethane (Figure 2C). At necropsy, the palpable masses 
originally detected in the Nlrx1-/- animals were identified 
as markedly enlarged spleens (Figure 2D). Spleens from 
all animals were weighed and those from the urethane 
treated Nlrx1-/- mice were indeed significantly larger than 
all of the other genotypes and treatments (Figure 2E). No 
gross lesions were identified in any additional tissues or 
organs. Following urethane treatment, Nlrx1 expression 
was increased in wild type animals that were resistant to 
histiocytic sarcoma (Figure 2F).
NLRX1 suppresses the development of 
histiocytic sarcoma
The increased urethane sensitivity observed in the 
Nlrx1-/- mice was directly correlated with splenomegaly. 
Subsequent histopathological assessments by two board 
certified veterinary pathologists (T.L.R. and S.C.O.) 
revealed that spleens from the urethane treated Nlrx1-/-
 mice were characterized by a significant expansion of the 
white pulp by high numbers of pleomorphic, mononuclear 
cells with frequent mitotic figures, thus consistent with 
a diagnosis of histiocytic sarcoma (Figure 3A-3B). No 
significant pathology was observed in the spleens from the 
saline treated wild type and Nlrx1-/- mice or the urethane 
treated wild type animals (Figure 3A). A semi-quantitative 
assessment of spleen histopathology, based on number of 
lesions and percent area affected (scored on a scale of 0 – 
3), revealed a significant increase in the spleen lesion score 
for the urethane treated Nlrx1-/- mice compared to all other 
genotypes and treatments (Figure 3C). Additional flow 
cytometry assessments of spleen cellularity, conducted at 
the time of harvest, confirmed the increased numbers of 
monocyte derived cells in the Nlrx1-/- spleens compared 
to the wild type. T-cell, B-cell, and NK-cell populations 
were not significantly different between wild type and 
Nlrx1-/- spleens (data not shown). Immunohistochemistry 
for MAC387 was performed and neoplastic cells showed 
strong cytoplasmic positive staining (Figure 3D). Based 
on these results, our data suggests that macrophages are 
the dominate cell population associated with histiocytic 
sarcoma in the Nlrx1-/- mice. Together, these data suggest 
that NLRX1 functions to attenuate histiocytic sarcoma 
induced by urethane and further support a role for this 
unique NLR in tumor suppression.
NLRX1 attenuates urethane induced 
tumorigenesis in the lung and inflammation in 
the liver
Typically, lung cancer progression is much slower 
in the urethane model, especially in C57Bl/6 mice and 
pathology is usually evaluated at least 24 weeks following 
the initial exposure. However, due to the sensitivity of 
the Nlrx1-/- mice to urethane and the rapid development 
of histiocytic sarcoma in the spleen, we evaluated lung 
histopathology 14 weeks following the initial exposure 
to urethane. In the wild type mice, we observed a small 
number of lesions in each treated animals consistent 
with urethane exposure (Figure 4A). Similar lesions 
were also observed in the Nlrx1-/- mice (Figure 4A). 
However, in the urethane treated Nlrx1-/- animals, we 
observed significantly higher numbers of tumor lesions 
(mean = 4.7 lesions) compared to the wild type animals 
(mean = 1.3) as well as a significant increase in bronchial 
associated lymphoid tissue (BALT) not seen in the wild 
type animals (Figure 4B). Thus, even at this earlier time-
point in the urethane model, the wild type animals had 
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Figure 2: NLRX1 Improves Survival and Morbidity Following Urethane Exposure. A. Schematic of the urethane model. 
Nlrx1-/- and wild type mice received 7 injections of 1g/kg body weight of urethane in saline over the course of 7 weeks. B. Kaplan-Meier plot 
of Nlrx1-/- and wild type mouse survival. C. Nlrx1-/- mice demonstrated a significant decrease in weight gain over the course of the model 
compared to the wild type animals. D. Necropsy revealed palpable masses in the peritoneal cavity associated with hypersplenomegaly in the 
Nlrx1-/- mice. E. Urethane treatment resulted in significant increases in spleen weight in the Nlrx1-/- mice compared to wild type animals. F. 
Urethane treatment increases Nlrx1 expression in wild type mice. Data are representative of 3 independent studies. Nlrx1-/- urethane, n=10; 
wild type urethane, n=28; Nlrx1-/- saline, n=3; wild type saline, n=3. *p<0.05.
begun forming the characteristic lung lesions associated 
with urethane exposure and, consistent with the morbidity 
data and findings in the spleen, the Nlrx1-/- mice were 
more sensitive. At necropsy, we also collected the liver 
for microscopic evaluation. Histopathologic assessments 
revealed that urethane exposure increased liver 
extramedullary hematopoiesis (EMH) and perivascular 
inflammation in all of the treated animals when compared 
to untreated animals (Figure 4C). Moreover, we observed 
a significant increase in both parameters in the Nlrx1-/-
 mice compared to the wild type animals. In addition to 
the increased EMH and inflammation, we also observed a 
significant increase in liver necrosis in the urethane treated 
Nlrx1-/- mice (Figure 4C). This necrosis was not observed 
in the wild type animals. The increased mass formation in 
the lung and increased inflammation in the lung and liver 
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Figure 3: NLRX1 Attenuates the Development and Progression of Histiocytic Sarcoma. Evaluation of histopathology 
revealed that urethane treatment resulted in the development of histiocytic sarcoma in Nlrx1-/- mice. A. Evaluation of H&E stained sections 
revealed a significant expansion of the white pulp and increased monocyte populations in spleens from urethane treated Nlrx1-/- mice 
compared to the saline treated and urethane treated wild type animals. B. Higher magnification evaluation revealed that all of the lesions 
contained high-grade malignancies consisting of markedly pleomorphic monocytes containing multiple mitotic figures (arrow). C. Semi-
quantitative scoring of histopathology revealed a significant increase in spleen lesions in the Nlrx1-/- mice compared to the wild type animals 
following urethane treatment. D. Immunohistochemistry using MAC387 (Abcam) was utilized to better classify the pre-dominate cell 
populations present in the spleen. All of the monocytes associated with spleen lesions were strongly positive for MAC387, suggesting that 
they are predominately macrophages. Data are representative of 3 independent studies. Nlrx1-/- urethane, n=10; wild type urethane, n=28; 
Nlrx1-/- saline, n=3; wild type saline, n=3. *p<0.05.
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Figure 4: NLRX1 Attenuates Urethane Induced Lesions in the Lung and Liver. A. Evaluation of histopathology revealed that 
urethane exposure increased lung lesions in both Nlrx1-/- and wild type mice. B. Semi-quantitative scoring revealed a significant increase 
in bronchial associated lymphoid tissue (BALT) hyperplasia and the number of lesions in lungs harvested from urethane treated Nlrx1-/-
 mice. C. In addition to the lungs, urethane exposure also resulted in increased liver lesions in the wild type and Nlrx1-/- mice. Nlrx1-/- mice 
developed significant increases in extramedullary hematopoiesis, perivascular inflammation, and necrosis compared to wild type animals. 
Data are representative of 3 independent studies. Nlrx1-/- urethane, n=10; wild type urethane, n=28; Nlrx1-/- saline, n=3; wild type saline, 
n=3. *p<0.05.
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observed in the urethane treated Nlrx1-/- mice is consistent 
with previous reports that identify NLRX1 as a negative 
regulator of inflammatory signaling pathways [22]. 
Likewise, the increased necrosis in the liver is consistent 
with previously reported findings in other models that 
suggest a role for NLRX1 in the modulation of cell death, 
autophagy, and cell metabolism [12, 16].
Genes associated with cancer, cell death and 
autophagy are significantly up-regulated in 
histiocytic sarcoma in Nlrx1-/- mice
NLRX1 has been previously shown to modulate 
inflammatory signaling pathways, cell death, autophagy, 
and reactive oxygen species (ROS) production [8, 16]. To 
better address the signaling pathways that are dysregulated 
in the Nlrx1-/- mice during tumorigenesis, we profiled gene 
expression in the spleen following urethane exposure. 
Spleens were harvested from both urethane treated and 
untreated wild type and Nlrx1-/- animals and total RNA 
was extracted (Supplementary Figure 2). The RNA from 
3-5 randomly chosen spleens from each genotype and 
treatment were pooled in equal amounts and cDNA was 
generated (Supplementary Figure 2). Different random 
pools of RNA were evaluated on each Superarray. The 
expression of 241 genes was evaluated using a panel 
of Superarrays (Qiagen) chosen to evaluate pathways 
associated with cancer, inflammation, cell death, and 
autophagy using methods previously described by the 
authors [14]. Gene expression was determined following 
the manufacturer’s protocols, which are based on the ΔΔCt 
method. The expression of each gene on the array was first 
normalized to a panel of 8 housekeeping genes and the 
change in gene expression between the respective urethane 
treated versus untreated wild type and Nlrx1-/- spleens was 
determined. The change in gene expression between the 
wild type and Nlrx1-/- spleens was then calculated and 
displayed as the fold change for each gene on the various 
arrays.
Because it is such a rare disease, very little data 
exists regarding gene expression or biochemical signaling 
pathways that are dysregulated in histiocytic sarcoma. 
Thus, we initially sought to evaluate genes commonly 
associated with cancer signaling. This initial evaluation 
revealed that 64 genes associated with tumorigenesis 
were significantly up-regulated in Nlrx1-/- spleens with 
histiocytic sarcoma compared to the wild type (Figure 
5A). The genes with the greatest differences in expression 
(>1000 fold increase) included: Dsp, Sox10, Ccl2, Ocln, 
Pgf, Epo, Foxc2, and Adm (Figure 5A). Interestingly, all 
of these genes, with the exception of Foxc2, have been 
previously associated with various types of sarcoma 
in either human or rodent studies and increased CCL2 
gene expression has been directly correlated with 
histiocytic sarcoma in canine patients [23]. In addition to 
increased expression of cancer associated genes, we also 
observed increased expression of 76 genes associated 
with autophagy (Figure 5A). The genes with the greatest 
differences in expression (100-199 fold increase) 
included: Rps6kb1, Tgfb1, Ctsb, and Hspa8 (Figure 5A). 
NLRX1 has been previously shown to positively regulate 
autophagy following virus exposure [13]. However, in the 
current study, NLRX1 deficiency was found to result in the 
elevation of several autophagy genes. This may suggest 
that under the conditions evaluated in this study, NLRX1 
acts as a negative regulator of autophagy. However, it is 
important to note that changes in gene expression do not 
necessarily correlate to changes in protein expression. 
Therefore, additional studies into protein expression 
would be necessary to better elucidate the effects of 
NLRX1 on autophagy in HS. We also observed increased 
expression of 44 genes associated with cell death (Figure 
5B). These genes were further stratified based on general 
roles in either necrosis or apoptosis (Supplementary Figure 
3). Together, these data suggest that NLRX1 negatively 
regulates gene expression associated with autophagy, 
and more broadly cell death, during tumorigenesis. This 
finding is consistent with a previous study that found 
NLRX1 functions as a tumor suppressor through the 
regulation of TNF induced apoptosis [16].
Significant increases in serum CCL2 levels have 
been found in canine cases of disseminated histiocytic 
sarcoma [23]. Likewise, Ccl2 appears to be up-regulated 
in macrophages from Nlrx1-/- mice and was identified 
as being one of the genes with the greatest level of up-
regulation in the spleen during histiocytic sarcoma 
(Figures 1C and 5A). Thus, we evaluated serum protein 
levels of CCL2 by ELISA (Figure 5B). Consistent 
with the increased expression of Ccl2 in the spleen, we 
observed a significant increase in serum CCL2 levels 
following urethane treatment in Nlrx1-/- mice compared 
to the wild type animals (Figure 5B). Prior studies have 
also evaluated other pro-inflammatory cytokines in the 
context of histiocytic sarcoma, including IL-6 [23]. While 
these studies did not find any correlation between IL-6 
and tumor progression, this cytokine has been reported 
to be increased in the absence of NLRX1 [14]. Thus, we 
also evaluated serum protein levels of IL-6 by ELISA and 
found that the levels of this cytokine were significantly 
increased in urethane treated Nlrx1-/- mice compared 
to the wild type animals (Figure 5C). Together with the 
gene expression findings, these data show that NLRX1 
attenuates inflammation and tumorigenesis through the 
negative regulation of genes associated with cancer, 
autophagy, and cell death during histiocytic sarcoma.
NLRX1 negatively regulates NF-κB and AKT 
signaling in histiocytic sarcoma
In general, the genes and pathways that were found 
up-regulated were highly diverse and covered a broad 
spectrum of pathways associated with tumorigenesis. 
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This suggests that NLRX1 likely indirectly regulates 
these pathways through its effects on one or more essential 
regulatory pathways up-stream from the genes evaluated. 
Prior studies have shown that NLRX1 negatively regulates 
the type-I interferon response and the NF-κB signaling 
cascade following virus exposure [14, 15]. While no prior 
data has associated IFN signaling with the urethane model, 
several lines of evidence indicate that the urethane model 
is potentiated by inflammation associated with increases 
in NF-κB signaling [19, 24]. Evaluation of the gene 
expression data did not reveal any significant differences 
in expression among genes generally associated with 
IFN signaling between the wild type and Nlrx1-/- spleens. 
Further analysis of pathways that were enriched in 
the spleen following urethane treatment also did not 
identify the IFN signaling pathway as being significantly 
dysregulated (data not shown). Thus, IFN signaling does 
not appear to play a role in either histiocytic sarcoma 
or NLRX1 function in this model. However, unlike the 
findings of IFN signaling, we did observe significant 
differences in genes associated with the NF-κB signaling 
cascade (Figure 6A). Our analysis revealed that 54 genes 
Figure 5: Genes Associated with Cancer, Autophagy, and Cell Death Are Significantly Up-Regulated in NLRX1 
Deficient Mice during Histiocytic Sarcoma. Gene transcription was profiled from RNA collected from wild type and Nlrx1-/- spleens 
14 weeks following the initial saline or urethane exposure. A-B. Heatmap reflecting the change in gene expression of all genes associated 
with common cancer pathways, autophagy, and cell death that were identified as being significantly up-regulated in the spleen following 
urethane treatment of Nlrx1-/- mice compared to the urethane treated wild type animals. Analysis was based on the ΔΔCt method, where all 
data was standardized to the average gene expression for a panel of 8 housekeeping genes and normalized to the respective untreated Nlrx1-/- 
and untreated wild type spleens. Greater than a 2-fold change in gene expression was considered significant. Three - five randomly selected 
spleens from each genotype and treatment group were selected and pooled for profiling studies. C-D. A significant increase in serum IL-6 
and CCL2 levels were detected in the Nlrx1-/- mice compared to wild type animals 14 weeks after the initial urethane injection. Cytokine 
levels were determined by ELISA. Nlrx1-/- urethane, n=6; wild type urethane, n=10; Nlrx1-/- saline, n=3; wild type saline, n=3. *p<0.05.
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Figure 6: NLRX1 Negatively Regulates NF-κB and AKT Signaling during Tumorigenesis. A. Heatmap and fold change 
in expression of all genes associated with NF-κB signaling that were identified as being significantly up-regulated in the spleen following 
urethane treatment of Nlrx1-/- mice compared to the urethane treated wild type animals. Analysis was based on the ΔΔCt method, where all 
data was standardized to the average gene expression for a panel of 8 housekeeping genes and normalized to the respective untreated Nlrx1-/- 
and untreated wild type spleens. Greater than a 2-fold change in gene expression was considered significant. Three – five randomly selected 
spleens from each genotype and treatment group were selected and pooled for profiling studies. B. Evaluation of all gene expression data 
using Ingenuity Pathway Analysis revealed a significant increase in NF-κB and AKT signaling in Nlrx1-/- spleens following urethane 
exposure compared to wild type. Pink icons represents genes that were significantly up-regulated (>2 fold change in expression) in the 
Nlrx1-/- spleens compared to the change in expression observed in the wild type spleens following urethane treatment. Nlrx1-/- urethane, n=5; 
wild type urethane, n=5; Nlrx1-/- saline, n=5; wild type saline, n=5.
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associated with NF-κB signaling were significantly up-
regulated (> 2-fold increase in expression) in the spleens 
from urethane treated Nlrx1-/- mice compared to the wild 
type animals (Figure 6A). Two genes, Csf2 and Csf3, were 
found to have the highest fold change in expression (>1000 
fold) (Figure 6A). Seven additional genes had greater than 
100-fold changes in expression between the Nlrx1-/- and 
wild type spleens, including Agt, Fos, Tnfrsf10b, Il10, 
Ccl2, Egr1, and Egfr (Figure 6A). All expression data 
was analyzed using Ingenuity Pathway Analysis (IPA) to 
identify relationships and pathways that were enriched 
in the urethane treated Nlrx1-/- spleens compared to the 
wild type spleens. The IPA analysis confirmed that the 
NF-κB signaling pathway was significantly up-regulated 
during histiocytic sarcoma in the Nlrx1-/- mice (Figure 6B). 
These data are consistent with prior studies supporting a 
role for NLRX1 in the negative regulation of NF-κB [14]. 
The IPA analysis also revealed a significant increase in 
TNF signaling (Figure 6B), which is consistent with the 
recent study that suggested NLRX1 functions as a tumor 
suppressor through modulating this pathway in cancer 
cells [16]. Our IPA analysis further revealed a significant 
increase in the AKT signaling pathway (Figure 6B). 
This was unexpected, as no prior studies have shown an 
association between NLRX1 function and AKT signaling. 
Each pathway downstream of AKT signaling was found 
to be up-regulated in the absence of NLRX1 during 
histiocytic sarcoma (Figure 6B). While more studies are 
clearly necessary, these findings suggest that NLRX1 may 
also function, either directly or indirectly, to negatively 
regulate AKT signaling during cancer. Together, these data 
suggest that the sensitivity of the Nlrx1-/- mice to urethane 
is at least in part associated with the up-regulation of gene 
transcription associated with increased NF-κB and AKT 
signaling.
DISCUSSION
Traditionally, the roles of NLRX1 have 
predominately been studied in the context of host-
pathogen interactions. However, recent studies have 
expanded the function of this unique NLR to include roles 
in the regulation of metabolism, cell death, and cancer [12, 
16, 17]. The results obtained in the present study support 
previous findings and strongly suggest that NLRX1 
functions to attenuate tumor progression. Mechanistically, 
our data suggest that this is through the downregulation 
of NF-κB signaling, as this pathway is significantly up-
regulated in the Nlrx1-/- mice following urethane exposure. 
Thus, in the current study, we have identified NLRX1 
as an important tumor suppressor and characterized a 
group of genes downstream of NF-κB signaling that are 
significantly up-regulated in the Nlrx1-/- animals that 
contribute to the development of histiocytic sarcoma.
In addition to our current findings, prior studies have 
also evaluated NLRX1 in cancer utilizing either xenograft 
models or models of inflammation driven colorectal 
cancer [16, 17, 25, 26]. In the xenograft study, nude mice 
were injected with RKO colon carcinoma cells, where 
NLRX1 was either stably knocked down or overexpressed 
[16]. In the presence of TNF, NLRX1 knockdown 
resulted in significantly increased tumor volume, whereas 
overexpression attenuated tumor growth [16]. To evaluate 
the role of NLRX1 in CAC, tumorigenesis was induced in 
wild type and Nlrx1-/- mice by treating the animals with the 
chemical carcinogen azoxymethane (AOM) immediately 
prior to dextran sulfate sodium (DSS) exposure [17, 25, 
26]. In this model, inflammation associated with DSS 
exposure functions as a tumor promoter. The results show 
that Nlrx1-/- mice were significantly more sensitive to 
inflammation driven tumorigenesis compared to similarly 
treated wild type animals [17, 25, 26]. Significantly 
higher numbers and larger-sized polyps were observed in 
the Nlrx1-/- mice [17]. The Nlrx1-/- mice were also found 
to have increased colon inflammation associated with 
DSS exposure [17]. In both the xenograft as well as the 
AOM/DSS models, the loss of NLRX1 was suggested to 
have implications in cell death leading to tumorigenesis, 
which is supported by our data as well. Findings from the 
xenograft study suggest that NLRX1 appears to sensitize 
the cells to TNF induced cell death through a Caspase-8 
dependent mechanism and maintains ATP levels through 
the regulation of mitochondrial Complex I and Complex 
III activities [16]. A similar mechanism is described in 
the colitis associated cancer (CAC) studies [17]. In the 
CAC studies, in vivo tumorigenesis data was supported 
by correlations to murine embryonic fibroblast data 
that suggested NLRX1 expression mediates resistance 
to extrinsic apoptotic signals, while also conferring 
susceptibility to intrinsic apoptotic signals [17].
The results of the current study support a role 
for NLRX1 in mediating cell death under neoplastic 
conditions, but not in primary macrophages. Our study 
identified 44 genes associated with cell death that were 
upregulated in the spleens of Nlrx1-/- mice with histiocytic 
sarcoma. Interestingly, the majority of cell death genes 
upregulated in these mice were related to apoptosis; 
however, no clear link to either intrinsic or extrinsic 
apoptosis was identified. It is also unclear if the up-
regulation of genes associated with cell death was directly 
associated with the neoplastic macrophages or associated 
with the general tissue damage that occurred in the spleen 
during histiocytic sarcoma progression. To expand upon 
these findings, we conducted basic assessments of cell 
death associated with our proliferation studies using 
primary bone marrow derived macrophages. Under our 
experimental conditions, we did not observe a significant 
difference in cell death between the wild type and Nlrx1-
/- macrophages. Rather, we noted a significant increase 
in Nlrx1-/- cell proliferation. It is certainly possible that 
the increase in cell numbers that we observed could 
also be correlated with reduced cell death. In fact, 
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increased cell proliferation and reduced cell death are 
commonly observed when essential pathways associated 
with tumorigenesis are disrupted [27]. The increased 
Nlrx1-/- macrophage proliferation is consistent with the 
increased splenic macrophage proliferation observed by 
histopathology in the spleens during histiocytic sarcoma. 
Likewise, the increase in expression of genes, such as Ccl2 
and Csf3, which are NF-κB regulated cytokines associated 
with macrophage proliferation and recruitment, are also 
consistent with our in vivo findings. Thus, the role of 
NLRX1 in regulating cell death (and proliferation) in 
normal versus neoplastic cells warrants further study.
In the present study, we sought to extend the 
assessments of NLRX1 and evaluate additional pathways 
modulated by this unique NLR in the context of 
tumorigenesis. Prior studies have shown that NLRX1 is 
a member of the regulatory NLR sub-group and functions 
to inhibit inflammatory signaling cascades, including IFN 
and NF-κB signaling (reviewed in [8]). While we did not 
observe any role for dysregulated IFN signaling in the 
development of histiocytic sarcoma in the Nlrx1-/- mice, 
we did find a strong correlation between tumorigenesis 
and the up-regulation of genes associated with NF-κB 
signaling. Prior mechanistic studies have shown that 
NLRX1 interacts with TRAF6 to negatively regulate NF-
κB signaling [14]. The NF-κB signaling pathway directly 
regulates a wide range of biological functions beyond 
inflammation and is associated with almost every hallmark 
of cancer [27]. In the context of histiocytic sarcoma, 
there is a paucity of data pertaining to NF-κB signaling. 
Beyond a few incidental observations, no detailed studies 
have comprehensively evaluated this signaling pathway 
in histiocytic sarcoma. However, NF-κB signaling has 
been evaluated in other types of sarcoma. For example, 
in human hemangioma and angiosarcoma lesions, high 
levels of RelA and strong activation of the NF-κB/IL-6/
STAT3 signaling axis has been previously reported [28]. 
These human data were complemented by studies using 
Ink4a/Arf deficient mice, which recapitulate genetic traits 
observed in human angiosarcoma patients and xenograft 
mice. In these models, animals developed angiosarcoma 
in the lung, liver, and spleen and systemic inhibition of 
Ikkβ, IL-6 or STAT3 significantly inhibited angiosarcoma 
growth [28]. In other sarcomas, inhibition of the NF-κB 
pathway has also been shown to significantly attenuate 
tumorigenesis. In a study utilizing a myxoid liposarcoma 
cell line, inhibition of the NF-κB signaling pathway was 
shown to decrease cell viability, reduce phosphorylation 
of NF-κB proteins, and attenuate caspase-3 regulated 
apoptosis [29]. Interestingly, the human metadata analysis 
described in the current study found the greatest decrease 
in NLRX1 expression in myxoid liposarcoma (Figure 1). 
This suggests a possible link between reduced NLRX1 
levels and increased NF-κB signaling in this neoplasm.
In addition to up-regulation of the NF-κB cascade, 
we also observed increased AKT signaling during 
histiocytic sarcoma in the Nlrx1-/- mice. This result was 
quite unexpected as no prior studies have associated 
NLRX1 with AKT signaling. However a related 
protein, AIM2, has recently been shown to attenuate 
the progression of colon tumorigenesis, in part, through 
reducing AKT activation [30]. In this study, Aim2-/- mice 
were found to be highly sensitive to colitis associated 
colorectal cancer. The increased tumor burden in these 
mice was significantly attenuated in those animals treated 
with an AKT inhibitor, suggesting that up-regulation of 
this pathway is associated with tumorigenesis [30]. Unlike 
the NF-κB pathway, the contribution of AKT signaling in 
histiocytic sarcoma has been previously reported [31]. 
In human specimens, immunohistochemistry revealed 
high levels of p-AKT expression in 9 of 10 histiocytic 
sarcoma samples [31]. These human data were further 
supported using a novel Pten+/- Ink4a/Arf-/- double mutant 
mouse model of histiocytic sarcoma. In this model, loss 
of PTEN results in aberrant activation of the PI3K/AKT 
signaling pathway, as well as, the RAS/MAPK pathway 
[31]. Ultimately, this results in increased AKT, ERK1 and 
ERK2 phosphorylation and the eventual development 
of histiocytic sarcoma [31]. Interestingly, lymphomas 
arising in the Ink4a/Arf-/- mice did not show this increase 
in AKT signaling compared with normal tissue from wild 
type animals, suggesting that increased AKT signaling is 
specific to histiocytic sarcoma in this model [31].
We identified 194 genes up-regulated in the Nlrx1-
/- mice following urethane administration that were 
associated with cancer signaling, autophagy and NF-
κB signaling. Many interesting targets were identified 
that have not been previously associated with either 
histiocytic sarcoma or NLRX1 function. Of the individual 
genes and proteins that were found to be significantly 
dysregulated, IL-6 and CCL2 are highly interesting. We 
observed increased systemic levels of IL-6 in the serum 
of the Nlrx1-/- mice (Figure 5). In canine patients, previous 
reports have observed significant increases in IL-6 in 
metastatic splenic hemophagocytic histiocytic sarcoma 
[32]. Likewise, as mentioned above in human patients 
and mouse models, prior studies evaluating the NF-κB/
IL-6/STAT3 axis in other types of sarcoma have reported 
increased IL-6 signaling and attenuation of tumorigenesis 
following treatment with IL-6 inhibitors [28]. Together, 
these findings suggest a major role for IL-6 in disease 
pathogenesis. Increased IL-6 levels have been previously 
reported in the Nlrx1-/- mice in other models associated 
with pathogen infection [14]. The direct association 
between NLRX1 and IL-6 signaling is presumed to result 
from increased NF-κB signaling found in the absence 
of NLRX1. A recent paper showed that enhanced IL-6 
in Nlrx1-/- mice is consequential, as anti-IL6R therapy 
completely reduced colon polyps in these animals [25]. 
However, it is also important to note that increased IL-6 
could also be an indirect response to the animal’s clinical 
decline, rather than a direct effect of NLRX1 function 
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on tumorigenesis. Additional mechanistic insight will 
be necessary to better define the relationship between 
NLRX1, IL-6 and histiocytic sarcoma pathogenesis. The 
increase in CCL2 (MCP-1), both ex vivo and in vitro is 
also an intriguing observation. Transcription of CCL2 
is highly regulated by NF-κB and the cytokine displays 
potent monocyte chemotactic activity. Increased CCL2 
has been previously reported in veterinary patients with 
histiocytic sarcoma [23]. In this prior study, serum levels 
of CCL2 were significantly increased in dogs diagnosed 
with disseminated histiocytic sarcoma compared to 
healthy control animals [23]. While we focused on IL-6 
and CCL2, many of the other genes identified are also 
highly interesting and should provide significant insight 
related to histiocytic sarcoma pathogenesis.
NLRX1 is a novel member of a unique regulatory 
sub-group of NLR family members that functions 
to negatively regulate diverse biochemical signaling 
cascades. Members of this regulatory sub-group function 
to control aberrant inflammation and other biologically 
relevant pathways associated with a variety of human 
diseases, including cancer. Here, we have shown that 
NLRX1 functions to suppress tumorigenesis, in part, 
through the negative regulation of NF-κB signaling. 
These findings are consistent with previous studies that 
have characterized NLRX1 as a tumor suppressor in other 
cancer models. We anticipate that future studies will better 
define the role of NLRX1 in cancer. Additionally, we have 
uncovered an extensive number of genes and pathways 
that have not previously been associated with histiocytic 
sarcoma. Thus, further studies of these pathways and 
dysregulated genes should identify novel targets for future 




The generation and characterization of Nlrx1-/- mice 
have been previously described [14]. All experiments were 
conducted with 6 - 22 week old C57Bl/6 female mice. 
All animals were maintained under SPF conditions and 
received 5010 chow (LabDiet) and water ad libitum. All 
experiments were conducted in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals and 
were conducted under institutional IACUC approval.
Bone marrow derived macrophage studies
Bone marrow derived macrophages (BMDMs) were 
isolated from the femurs of C57Bl/6 and Nlrx1-/- mice 
using standard procedures [18]. The cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% 
fetal bovine serum (FBS), 20% L929-conditioned cell 
culture supernatant, 1x L-glutamine, and 1x non-essential 
amino acids for 5-7 days. BMDMs were sub-cultured with 
or without serum overnight. Both live and dead cells were 
counted at designated intervals using either trypan blue 
and a hemacytometer or PI staining and quantification 
with an automated cell counter (Cellometer Vision from 
Nexcelom Bioscience) following the manufacturer’s 
protocols. A minimum of 1000 cells for each genotype 
and treatment were counted using the automated system. 
Supernatants were removed for cytokine measurements 
and total RNA was collected for gene expression analysis.
Induction and assessment of histiocytic sarcoma
To assess the pathobiological effects of urethane, 
all mice were subjected to once weekly, i.p. injections of 
urethane (Sigma) at 1 g/kg diluted in 1X PBS for a total 
of 7 weeks [19]. Body weight, physical condition, and 
behavior were assessed at least 3 days per week throughout 
the course of each study. Mice were harvested at 7 or 14 
weeks post-urethane exposure or when moribund. On the 
day of harvest, mice were euthanized via CO2 asphyxiation 
and approximately 1 ml of blood was collected by cardiac 
puncture. The lung, liver, and spleen were harvested from 
each animal. Portions of each tissue were placed either 
in formalin for histopathology or frozen and stored in the 
-80 for RNA/protein analysis. Samples of spleen were also 
prepared for flow cytometry.
Histopathologic examination
Formalin-fixed tissues were routinely processed 
for histopathology. The paraffin-embedded tissues were 
sectioned at 5 μm and prepared for hematoxylin and eosin 
(H&E) staining. H&E stained sections were evaluated and 
scored by a board-certified veterinary pathologist (T.L.R 
and S.C.O) while blinded to genotype and treatment. 
Immunohistochemistry for MAC387 (Abcam) was used 
to evaluate monocyte populations in the spleen.
Expression profiling
Total RNA was harvested from spleens following 
mechanical homogenization, lysis and RNA extraction 
using a FastRNA Pro Green Kit and the manufacturer’s 
protocols (MP Biomedicals). The purified RNA was 
quantified and 1μg of RNA was pooled from 3-5 individual 
mice prior to the cDNA reaction, for analysis using the RT2 
Profiler PCR Array Platform (SABiosciences). Samples 
were evaluated using the manufacturer’s protocols for the 
following arrays: PAMM-033Z; PAMM-084Z; PAMM-
011Z; PAMM-064Z; PAMM-025Z. Ingenuity Pathways 
Analysis (IPA) software was utilized to evaluate the array 
data. In addition to the profiling studies, RNA samples (5 
μg) were also individually archived using a cDNA Archive 
Kit (ABI) and specifically targeted transcription products 
were quantified by real time PCR using commercially 
available primer/probe sets (ABI). All experimental 
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samples were evaluated in triplicate and the relative 
expression was determined utilizing the ΔΔCt method by 
normalizing samples to the expression of the 18s rRNA 
housekeeping gene.
Human metadata analysis
Human NLRX1 expression was evaluated using 
a publically accessible microarray meta-analysis search 
engine (http://www.nextbio.com/b/search/ba.nb), as 
previously described [33]. The following array data series 
were analyzed to generate the human patient data: GSE7553; 
GSE66354; GSE32490; GSE37470; GSE34823; GSE7339; 
GSE36474; GSE50579; GSE9750; GSE28511; GSE29431; 
GSE19750; GSE7553; GSE29491; GSE2719; GSE49972; 
GSE13898; and GSE36982.
Statistical analysis
Data are presented as the mean +/- standard error 
of the mean (SEM). Analysis Of Variance (ANOVA) 
followed by either Tukey-Kramer HSD or Newman-
Keuls Post Test for multiple comparisons was performed 
on complex data sets for both individual experiments and 
composite data. Statistical significance for single data 
points were assessed by the Student’s two-tailed t-test. 
Survival curves were generated utilizing the product limit 
method of Kaplan and Meier and comparisons were made 
using the log rank test. In all cases, a p-value of less than 
0.05 was considered statistically significant.
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